title: Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.
abstract: BACKGROUND
  There are only limited data on sofosbuvir-based treatment regimens in hepatitis C virus (HCV) genotype 4-infected patients.
  
  
  OBJECTIVE
  To evaluate safety and efficacy of sofosbuvir-based triple-therapy in HCV genotype 4 infection.
  
  
  METHODS
  All HCV genotype 4-infected patients who started sofosbuvir-based triple-therapy at our two centres between January and June 2014 were prospectively included (N=24) and compared to genotype 4 patients treated with peginterferon/ribavirin between January 2001 and December 2012 (N=63).
  
  
  RESULTS
  The demographics in the sofosbuvir group and the controls were comparable (males 87.5% and 82.5%; mean age 46.7±9.0 years and 42.0±9.8 years, respectively). Sustained virological response was achieved in 83.3% in the sofosbuvir group and in 47.6% of controls (P=0.003). Fatigue (P=0.007), flu-like (P=0.015), gastrointestinal (P<0.001), dermatologic (P<0.001) and psychiatric symptoms (P=0.022) were more common in the control group.
  
  
  CONCLUSIONS
  In our real-life cohort, sofosbuvir-based triple therapy confirmed its high efficacy and safety for chronic genotype 4 hepatitis C.
authors.affiliation: I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Malte H
authors.initials: MH
authors.lastname: Wehmeyer
authors.affiliation: I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Sabine
authors.initials: S
authors.lastname: Jordan
authors.affiliation: I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Lüth
authors.affiliation: I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Hartl
authors.affiliation: Institute for Interdisciplinary Medicine at the Asklepios Klinik St. Georg, Hamburg, Germany.
authors.forename: Albrecht
authors.initials: A
authors.lastname: Stoehr
authors.affiliation: I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Christiane
authors.initials: C
authors.lastname: Eißing
authors.affiliation: I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg Site, Germany.
authors.forename: Ansgar W
authors.initials: AW
authors.lastname: Lohse
authors.affiliation: Institute for Interdisciplinary Medicine at the Asklepios Klinik St. Georg, Hamburg, Germany.
authors.forename: Jörg
authors.initials: J
authors.lastname: Petersen
authors.affiliation: Institute for Interdisciplinary Medicine at the Asklepios Klinik St. Georg, Hamburg, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Buggisch
authors.affiliation: I. Department of Internal Medicine, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg Site, Germany. Electronic address: j.schulze-zur-wiesch@uke.de.
authors.forename: Julian
authors.initials: J
authors.lastname: Schulze Zur Wiesch
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D005858:Germany; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000009:adverse effects* / Q000627:therapeutic use*; D062606:Tertiary Care Centers; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin; D000069474:Sofosbuvir
keywords: Direct acting antivirals; HCV; SVR; Sustained virological response